<rss version="2.0">
<channel>
<title>MindBranch: Biotechnology</title>
<description>Biotechnology market research products provide analysis of the latest trends, developments and market data for this industry.  Research information will help you make informed business decisions.</description>
<link>http://www.mindbranch.com/catalog/find.jsp?cat=bt</link>
<item>
<title>Biotechnology Sector</title>
<link>http://www.mindbranch.com/products/R3470-3265.html</link>
<description> <![CDATA[The US biotechnology industry includes about 1,500 companies with combined annual revenue of about $70 billion. Major companies include Amgen, Biogen Idec, Genentech (owned by Switzerland-based Roche), Genzyme, Life Technologies, and Monsanto. Because many drugs are now developed using biotechnology, the biotechnology and pharmaceutical industries overlap considerably.  COMPETITIVE LANDSCAPE  Demand for biotechnology research in the fields of medicine, agriculture, food, and science is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise ]]></description>
<pubDate>Mon, 16 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Monoclonal antibodies: 2009 update</title>
<link>http://www.mindbranch.com/products/R313-57650.html</link>
<description> <![CDATA[ Introduction   The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.   Scope   Comprehensive financial strategic analysis of the mAb market out to 2014  Global sales forecasts to 2014 for marketed and Phase III mAb products  Analysis of market trends by product, company, geography, therapy area, technology and target type  Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics   Highlights   The global prescription pharmaceutical market is expected to face a decline in sales over 2012 to 2013 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.  Over the forecast period monoclonal antibodies ]]></description>
<pubDate>Mon, 02 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Dealmaking and Industry Outlook: Neurological Disease</title>
<link>http://www.mindbranch.com/products/R55-680.html</link>
<description> <![CDATA[The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying
causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon
be superseded by new approaches. The key to future success in this therapy area is a better understanding of
the underlying biomarkers, genes, and disease pathways that lead to disease. Pharma companies have scoured
the ranks of available drug targets, technologies, and innovation in neurological diseases and have executed a
plethora of acquisitions and deals. In this report, we categorize more than 300 deals in the neurological disease
industry for a 32-month period including 2007, 2008, and the first eight months of 2009. We assess the neurology
market and its major players as well as analyze the deals that companies are executing and the business
strategies they are deploying to gain future success.  
 Questions ]]></description>
<pubDate>Mon, 02 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Algae For Fuel, Algal Oil, Biofuels, Biodiesel, Ethanol And The Future Of Petroleum And Green Energy</title>
<link>http://www.mindbranch.com/products/R3503-8.html</link>
<description> <![CDATA[This research provides an overview on what could become one of the most significant technological and economic events of the early 21st century: turning algae into fuel, i.e. algal oil, on a commercial scale. If this feat is accomplished, and it&rsquo;s not certain it will be, it will have dramatic, disruptive consequences to oil producers, oil refiners, ethanol, biodiesel and other biofuels producers, biotechnology companies, agricultural producers, consumers, motor vehicle makers, regulators, R&D activities and investors, among others. 
  
However, from this change will come enormous opportunities, including less dependence on petroleum oil, more geopolitical independence, reductions in CO2 and global warming, technological advancements, very large, new industries and markets, and huge profits. 
  
The report provides a review of algae in terms of biology, classifications, photosynthesis and applications and discusses algae for fuel in terms of its history, applications, cultivation technologies and R&D. Analysis of the algal ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Dextrins Food &amp; Industrial applications, Products &amp; Markets</title>
<link>http://www.mindbranch.com/products/R537-14.html</link>
<description> <![CDATA[Dextrins belong to a class of low-molecular-weight carbohydrates degradation products made from starch manufactured by a process called pyrolysis.  During pyrolysis, dry, powdered starch is treated with acid in a suitable reactor and heated while mixing. Depending on the type of starch used, the reaction conditions, and the point at which the reaction is stopped, a very large number of different products can be made for use in industrial and food applications. They find widespread use in industry, due to their non-toxicity. They are used as water-soluble glues, as thickening agents in food processing, and as a binding agent in pharmaceuticals.  
Dextrinization can be accomplished using either a mineral acid or an organic acid as a catalyst.  Hydrochloric acid is widely used in the manufacture of dextrins. A dextrin are characterized by its solubility in water, viscosity, color, pH, moisture, reducing sugar value, molecular weight distribution, and many ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>CWS (cold water swelling) / Spray Cooked starches - Applications, Products and Markets</title>
<link>http://www.mindbranch.com/products/R537-15.html</link>
<description> <![CDATA[Cold water swelling and spray cooked starches are marketed heavily for instant preparation and convenience aspects of food preparation. Granular cold water swelling/soluble starches are produced by treatment with an alcohol and a strong base to effect swelling of the starch granules and conversion to a form having increased cold water solubility. Spray cooked starches with properties similar as cold water swelling starches by simultaneous cooking and spry drying in a chamber maintained at certain temperature and specific pressure. These ingredient offer unique cold swelling properties and have all properties of granular starch and do not require cooking. Several of sources of starches such as dent, waxy, tapioca and potato offer their unique functionalities.   
Specialty starches labeled instant, granular or cold water-swelling hydrate at lower temperatures and eliminate the heating step. In addition to convenience and significant savings in time, labor, energy and equipment, these also improve the quality ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Global Stem Cell and Advanced Technologies Market</title>
<link>http://www.mindbranch.com/products/R3719-25.html</link>
<description> <![CDATA[The stem cell market is growing rapidly due to increasing regulatory approval and public acceptance bodies. The benefits of stem cell therapy are attracting an increasing number of patients. The product submarket for human and embryo stem cells are expected to drive the growth of the overall market. In addition, intensive R&D efforts and the increasing investments into research on stem cells therapy are soon expected to improve the efficacy of stem cell treatment. However, the high cost of the therapy may affect market growth. 
  
The global stem cell market is estimated to be $88.3 billion by 2014, growing at a CAGR of 14.8 % from 2009 to 2014. The U.S. currently holds a 60% share of the global stem cell market; and forms an especially lucrative market for areas such as bone marrow transplantation through stem cells. This research report will help stakeholders gain a better understanding ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Opportunities in Human Embryonic Stem Cell (hESC) Products</title>
<link>http://www.mindbranch.com/products/R3663-8.html</link>
<description> <![CDATA[Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body, providing tremendous therapeutic potential. 
  
Human ESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of primate embryonic stem cells occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow human embryonic stem cells derived from human blastocysts. 
  
As a result of these significant accomplishments at the University of Wisconsin, the Wisconsin Alumni Research Foundation (WARF) filed a ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology (Pharmaceuticals) Report</title>
<link>http://www.mindbranch.com/products/R3468-11441.html</link>
<description> <![CDATA[The Global Biotechnology Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Global Biotechnology Industry. Using the unique Plimsoll method of analysis, each of the top 500 Biotechnology Companies is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just as easily as it can emphasise ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Physically Modified Starches Applications, Products and Markets</title>
<link>http://www.mindbranch.com/products/R537-16.html</link>
<description> <![CDATA[Recent developments in starch technology are the development and marketing of physically modified starches that perform similar to chemically modified starches in food applications.  National led this development by introducing product line under brand name NOVATIONTM series of functional native starches which offer full functionality of premium modified  starches with a simple 'corn or tapioca starch' label. These products are process tolerant and shelf stable, attributes never before possible with native starches. Introduced in 1996 and widely used throughout the world, these products are now growing as the consumers seek variety in their diet and demonstrate a taste for foods from other lands and cultures. Food product developers are responding to this demand by offering new products with unique, exotic profiles.   

Physically modified starches represent the greatest opportunity for growth in the starch industry.  As the desire to provide cleaner labels or &ldquo;pantry friendly&rdquo; ingredients, ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Three Bundled Reports 1: Dextrins: Food &amp; Industrial 2: CWS (cold water swelling) / Spray Cooked starches 3: Physically Modified Starches  each with Applications, Products and Markets</title>
<link>http://www.mindbranch.com/products/R537-17.html</link>
<description> <![CDATA[The three starch derivatives cover the most active areas of food ingredients to meet the growth of convenience, snacks, clean labeling.  
 Dextrin Report  Dextrins belong to a class of low-molecular-weight carbohydrates degradation products made from starch manufactured by a process called pyrolysis.  During pyrolysis, dry, powdered starch is treated with acid in a suitable reactor and heated while mixing. Depending on the type of starch used, the reaction conditions, and the point at which the reaction is stopped, a very large number of different products can be made for use in industrial and food applications. They find widespread use in industry, due to their non-toxicity. They are used as water-soluble glues, as thickening agents in food processing, and as a binding agent in pharmaceuticals.  
Dextrinization can be accomplished using either a mineral acid or an organic acid as a catalyst.  Hydrochloric acid is widely used in the manufacture ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Freedonia Focus on Biologicals</title>
<link>http://www.mindbranch.com/products/R761-1052.html</link>
<description> <![CDATA[This report discusses US biologicals demand  for the years 2003 and 2008, with forecasts for 2013.  Topics covered include market size, product and market segmentation, technological and product development, regulatory considerations, market environment, product and market forecasts, industry composition and leading participants.  Product segments include recombinant proteins, monoclonal antibodies (Mabs), vaccines, blood and blood derivatives, and other biologicals;  market segments cover pharmacy, ambulatory health care, hospital, other health care markets, and other markets.  This 20 page report also includes a highlights summary and a resources ]]></description>
<pubDate>Sat, 31 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Crop Protection China Market Opportunities and Challenges</title>
<link>http://www.mindbranch.com/products/R3539-252.html</link>
<description> <![CDATA[China is a traditional agricultural country, with a total area of 5,000 billion square meters stricken by plant diseases and insect pests each year. With only 7% of the world&rsquo;s arable land, China has fed 22% of the world&rsquo;s population, which is a great marvel in history. How do Chinese people achieve this? One answer is making good use of crop protection.   
China is a traditional agricultural country, with a total area of 5,000 billion square meters stricken by plant diseases and insect pests each year. With only 7% of the world&rsquo;s arable land, China has fed 22% of the world&rsquo;s population, which is a great marvel in history. How do Chinese people achieve this? One answer is making good use of crop protection. 
  
Crop protection is widely applied across the world and plays important roles in guaranteeing the safety of agricultural production and the quality of ]]></description>
<pubDate>Fri, 30 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Protein Kinase Therapeutics in Oncology - Where to Commercialize?</title>
<link>http://www.mindbranch.com/products/R474-346.html</link>
<description> <![CDATA[ This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.
  
 

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies&rsquo; portfolio planning and new product planning by:
 
 

  Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
 
 

  Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for ]]></description>
<pubDate>Thu, 29 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Acorda Therapeutics, Inc. - SWOT Analysis</title>
<link>http://www.mindbranch.com/products/R313-56999.html</link>
<description> <![CDATA[Datamonitor's Acorda Therapeutics, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. Acorda Therapeutics, Inc. - SWOT Analysis examines the company&rsquo;s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.   Acorda Therapeutics (Acorda) is a commercial-stage biotechnology company that develops and market therapies to restore function in persons with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the central nervous system (CNS). Acorda&rsquo;s marketed products include Zanaflex Capsules (tizanidine hydrochloride) and Zanaflex (tizanidine hydrochloride) tablets. The company primarily operates in the US. It is headquartered in Hawthorne, New York, and employed 174 people as of February 2009.  The company recorded revenues of $47.7 million during the financial year (FY) ended December 2008, an increase of 21.1% over FY2007. The increase in revenues was due to an increase in prescriptions ]]></description>
<pubDate>Mon, 26 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Future of Green Biotechnology in China</title>
<link>http://www.mindbranch.com/products/R3539-254.html</link>
<description> <![CDATA[This report is the unique and latest one available in the world to provide good understanding about Green Biotechnology (GB) in China and to find out business opportunities in this field. The first edition of this report is finished soon in October 2009. 
  
Green biotechnology (GB) is mainly based on genetically modified technology and fermentation technology. Over the last thirty years, China&rsquo;s GB industry has been developing stably. Chinese scientists have applied biotechnology techniques to develop many novel crop varieties that are suited to local farming conditions and can cope with challenges. More and more products in agriculture have adopted biotechnology, and production scale has been enlarged. Increasing use of green biotechnology in agricultural production can bring a lot of benefits.
  
Driven by its substantial benefits for people, environment and economy, China&rsquo;s GB industry has witnessed fast development and has played an increasingly important role in Chinese ]]></description>
<pubDate>Mon, 19 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-31203.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Biotechnology in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   Biotechnology is the application of science and technology to living organisms as well as parts, products and ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology in Australia - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-30490.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Biotechnology in Australia industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   The Organisation for Economic Co-operation and Development (OECD) definition of biotechnology states that it is the application of ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Scientific Research in Australia - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-30395.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Scientific Research in Australia industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   Companies in this industry undertake research in the agricultural, biological, physical or social sciences. The majority of ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Crucell N.V. - SWOT Analysis</title>
<link>http://www.mindbranch.com/products/R313-57048.html</link>
<description> <![CDATA[Datamonitor's Crucell N.V. - SWOT Analysis company profile is the essential source for top-level company data and information. Crucell N.V. - SWOT Analysis examines the company&rsquo;s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.   Crucell is a biopharmaceutical company engaged in discovering, developing and commercializing vaccines and antibodies against infectious diseases. The company's product portfolio is focused on three distinct areas: paediatric, travel and endemic, and respiratory. The company primarily operates in Europe, North America and Asia. It is headquartered in Leiden, the Netherlands and employed 1,126 people as of December 2008.  The company recorded revenues of E267.2 million ($393.1 million) during the financial year (FY) ended December 2008, an increase of 31.1% over FY2007. The increase in revenues was due to strong sales of paediatric vaccines, travel and endemic vaccines as well as a doubling in license ]]></description>
<pubDate>Fri, 16 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Elan Corporation, plc - SWOT Analysis</title>
<link>http://www.mindbranch.com/products/R313-56961.html</link>
<description> <![CDATA[Datamonitor's Elan Corporation, plc - SWOT Analysis company profile is the essential source for top-level company data and information. Elan Corporation, plc - SWOT Analysis examines the company&rsquo;s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.   Elan is a neuroscience based biotechnology company focused on discovering, developing, manufacturing and marketing therapies in neurology, autoimmune diseases, and severe pain. Elan's flagship product, Tysabri (natalizumab), is being marketed in collaboration with Biogen Idec for the treatment of multiple sclerosis and Crohn's disease. Other marketed products in its portfolio include Prialt (ziconotide), Maxipime (cefepime hydrochloride) and Azactam (aztreonam for injection, USP). Elan is headquartered in Dublin, Ireland and employed 1,687 people as of December 2008.  The company recorded revenues of $1,000.2 million during the financial year (FY) ended December 2008, an increase of 31.7% over FY2007. The increase was due to ]]></description>
<pubDate>Fri, 16 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Plunkett's Health Care Technologies Overview 2010 (Summary)</title>
<link>http://www.mindbranch.com/products/R207-602.html</link>
<description> <![CDATA[This summary contains the complete technologies section excerpted from the highly-acclaimed Plunkett's Health Care Industry Almanac. This report will be your ready-reference guide to new and developing health care technologies. Technology topics range from stem cells, to new drug delivery systems, to gene therapies. The report includes several statistical tables. You'll find the information you need in this carefully-researched report.
]]></description>
<pubDate>Fri, 16 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology: Global Industry Guide</title>
<link>http://www.mindbranch.com/products/R313-56811.html</link>
<description> <![CDATA[Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the Biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.   Scope of the Report       Contains an executive summary and data on value, volume and segmentation    Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies   Incorporates in-depth five forces competitive environment analysis and scorecards    Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).    Includes a five-year forecast of the industry   Highlights   The global biotechnology market grew by 8.8% in 2008 to reach a value of $216.3 billion.  In 2013, the global biotechnology market ]]></description>
<pubDate>Wed, 14 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>The Human Genome Sequencing Center at Baylor College of Medicine Relies on Quantum's StorNext Software for Data Management</title>
<link>http://www.mindbranch.com/products/R104-40214.html</link>
<description> <![CDATA[ This IDC Buyer Case Study examines how one research institution utilizes Quantum's StorNext data management software to support its growing storage ]]></description>
<pubDate>Thu, 08 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Lonza Group Ltd - SWOT Analysis</title>
<link>http://www.mindbranch.com/products/R313-57076.html</link>
<description> <![CDATA[Datamonitor's Lonza Group Ltd - SWOT Analysis company profile is the essential source for top-level company data and information. Lonza Group Ltd - SWOT Analysis examines the company&rsquo;s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.   Lonza Group (Lonza) is a supplier of pharmaceutical active ingredients to the pharmaceutical, healthcare, and life science industries. The company operates mainly in Europe and North America. It is headquartered in Basel, Switzerland and employs more than 8,400 people.  The company recorded revenues of CHF2,937 million (approximately $2,721 million) during the financial year ended December 2008 (FY2008), an increase of 2.3% over FY2007. The operating profit of the company was CHF441 million (approximately $408.6 million) during FY2008, an increase of 8.1% over FY2007. The net profit was CHF419 million (approximately $388.2 million) in FY2008, an increase of 39.2% over FY2007.   Scope of the ]]></description>
<pubDate>Thu, 08 Oct 2009 00:00:00 EST</pubDate>
</item>
</channel>
</rss>
